Trans-Pacific Partnership: Pharma's payoff for Obamacare neutrality

Comment icon 0 Comments
In 1993 the new Clinton administration decided to make health care reform the signature issue of its first term. Bill Clinton appointed his... Read more

Health insurers balance long- and short-term moves but can pharma?

Comment icon 0 Comments
Commercial success for a new drug brand increasingly depends on whether and, how much, third-party payers will reimburse for it. As more physicians... Read more

One week, three lessons for pharma

Comment icon 0 Comments
The past week in pharma was one of those times when just setting the news items alongside one another in the proper order can tell someone... Read more

When a pharma spokesman advocates value-based pricing

Comment icon 0 Comments
The Forbes columnist and pharma cheerleader, John La Mattina, left Pfizer in 2008 as their R&D head with a $22.6 million package after... Read more

Less research training in medical school? That's actually good

Comment icon 0 Comments
In Sunday's Health section of the Inquirer, reporter Ilene Raymond Rush interviewed the dean of Temple's medical school, Arthur Feldman. The... Read more

Which long-term road for GlaxoSmithKline

Comment icon 0 Comments
GlaxoSmithKline (GSK), the British pharmaceutical company with U.S. operations in the Philadelphia area, reported 2015 first quarter earnings... Read more

Drug pricing: The problem and some band-aids

Comment icon 0 Comments
Two stories surfaced this week that provide more examples of how increasing drug prices have gotten totally out of hand. In the first one... Read more

Self-dealing physicians and a bad trade deal

Comment icon 0 Comments
The costs of health care and affordable access to it are made worse by high drug prices that keep rising many times faster than the cost living... Read more